ProKidney (PROK) AI Stock Analysis

ProKidney

(BMV:PROK)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Clinical progressProgress toward a Phase 3 readout indicates that rilparencel is advancing through a pivotal development stage. Continued enrollment keeps the program moving toward an important efficacy assessment and preserves the potential for a meaningful clinical and commercial milestone.

Negative Factors

Severe cash burnLarge and continuing cash outflows show that the business is not self-funding and has not moved toward breakeven. Sustained development spending will require substantial financing, making future operations dependent on access to external capital.

ProKidney (PROK) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 435.45M
Dividend Yield: ―
Average Volume (3M): 14.90K
Price to Earnings (P/E): -2.3
Beta (1Y): -4.01
Revenue Growth: 39.88%
EPS Growth: 11.10%
Country: Mexico
Employees: 231
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

ProKidney Business Overview & Revenue Model

Company Description

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived f...

ProKidney Risk Analysis

ProKidney disclosed 92 risk factors in its most recent earnings report. ProKidney reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.Our recurring losses, negative cash flows, and accumulated deficit raise substantial doubt about our ability to continue as a going concern.Q2, 2026

ProKidney Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:PROK against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GYRE	52Neutral	$482.98M	-22.90	-15.77%	―	16.83%	-494.61%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DMAC	51Neutral	$498.81M	-12.85	-77.68%	―	―	-3.42%
SANA	48Neutral	$769.36M	-3.38	-134.49%	―	―	28.46%
AKBA	45Neutral	$195.78M	-6.54	-93.74%	―	7.52%	35.69%
ARDX	43Neutral	$755.04M	-13.42	-36.00%	―	16.77%	4.11%

* Healthcare Sector Average

Performance Comparison

MX:PROK and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:PROK	Prokidney Corp.	24.86	-27.67	-52.67%
GYRE	Gyre Therapeutics Inc	4.55	-2.81	-38.11%
AKBA	Akebia Therapeutics	0.71	-1.41	-66.70%
ARDX	Ardelyx Inc	3.03	-2.89	-48.82%
DMAC	Diamedica Therapeutics	9.25	2.45	36.03%
SANA	Sana Biotechnology, Inc.	2.57	-2.00	-43.76%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

ProKidney AI Stock Analysis